The University of Texas M. D. Anderson Cancer Center will hold the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists.
Get the full story...
UC Davis researchers have defined a cellular process that promotes inflammation and, at the same time, found an important starting point for identifying and testing new drugs for diseases such as sepsis, rheumatoid arthritis, cardiovascular disease and some cancers.
Get the full story...
People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.
Get the full story...
Major depressive disorder is a common and complex condition that impacts about 15% of the population of the United States, yet very little is known about the mechanisms behind the psychiatric disorder. What is known is that there are clinical parallels between depressive symptoms and the symptoms of certain inflammatory disorders.
Get the full story...
Researchers at Cincinnati Children’s have issued the first study showing that a protein normally involved in blood clotting (fibrin), also plays an important role in the inflammatory response and development of rheumatoid arthritis. Inflammatory joint disease appears to be driven by the engagement of inflammatory cells with fibrin matrices through a specific integrin receptor, aMB2.
Get the full story...
A team of Cornell University scientists have discovered that a novel group of E. coli bacteria – containing genes similar to those described in uropathogenic and avian pathogenic E. coli and enteropathogenic bacteria such as salmonella, cholera, bubonic plague – is associated with intestinal inflammation in patients with Crohn’s disease in their research paper published July 12 by “The ISME Journal: Multidisciplinary Journal of Microbial Ecology.”
Get the full story...
A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE®) therapy. These findings were published online today by Annals of Internal Medicine.
Get the full story...
Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE® (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50.
Read the full story